Abstract | BACKGROUND: METHODS: For this purpose, relevant studies investigated safety and efficacy of PRRT in the patients with advanced RR-DTC and metastatic MTC were identified by searching Medline (Pubmed, Ovid, and Ebsco), Scopus, Embase, Web of Science, and Cochrane Library databases (from database inception to March 24, 2021). The review was performed according to the preferred reporting items for systematic reviews and meta-analyses ( PRISMA) statement. Searching was done independently by two investigators. Two researchers independently extracted the data and any disagreement was adjudicated by consensus. Quality of the studies was assessed using the tool of case reports/series in systematic reviews. RESULTS: Among 2284 related papers, 41 papers met the inclusion criteria. A total of 157 patients with RR-DTC were treated with PPRT. Biochemical and objective responses (partial and complete) were observed in 25.3 and 10.5% of patients, respectively. Among 220 patients with metastatic MTC, biochemical and objective responses were observed in 37.2 and 10.6% of the patients, respectively. Forty-six deaths were reported in 95 patients with advanced RR-DTC. In addition, 63 deaths were observed in 144 patients with metastatic MTC. Major side effects were reported in 124 patients treated with 90Y -based agent. In the patients treated with 177Lu-DOTA-TATE and 111In-Octreotide, mild and transient hematologic or renal complications were reported. CONCLUSION: Findings of the study revealed that in the absence of the established treatment for the patients with RR-DTC and metastatic MTC, PRRT could be effective with few adverse events. TRIAL REGISTRATION: PROSPERO registration number: CRD42019125245 .
|
Authors | Zohreh Maghsoomi, Zahra Emami, Ramin Malboosbaf, Mojtaba Malek, Mohammad E Khamseh |
Journal | BMC cancer
(BMC Cancer)
Vol. 21
Issue 1
Pg. 579
(May 20 2021)
ISSN: 1471-2407 [Electronic] England |
PMID | 34016077
(Publication Type: Journal Article, Systematic Review)
|
Chemical References |
- Iodine Radioisotopes
- Organometallic Compounds
- Radiopharmaceuticals
- Yttrium Radioisotopes
- indium-111-octreotide
- Yttrium-90
- lutetium Lu 177 dotatate
- Octreotide
|
Topics |
- Carcinoma, Neuroendocrine
(diagnosis, radiotherapy, secondary)
- Hematologic Diseases
(epidemiology, etiology)
- Humans
- Iodine Radioisotopes
(administration & dosage, adverse effects)
- Octreotide
(administration & dosage, adverse effects, analogs & derivatives)
- Organometallic Compounds
(administration & dosage, adverse effects)
- Radiation Injuries
(epidemiology, etiology)
- Radiation Tolerance
- Radiopharmaceuticals
(administration & dosage, adverse effects)
- Renal Insufficiency
(epidemiology, etiology)
- Thyroid Neoplasms
(diagnosis, pathology, radiotherapy, secondary)
- Treatment Outcome
- Yttrium Radioisotopes
(administration & dosage, adverse effects)
|